TEM Latest Press Releases

-- October 7, 2026 --

Tempus Announces Multi-Year Collaboration with Moderna and Merck Business Wire 8:30 AM

-- October 1, 2026 --

Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026 Business Wire 8:34 AM

-- September 28, 2026 --

Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation Business Wire 8:00 AM

-- September 21, 2026 --

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model Business Wire 9:14 AM

-- September 11, 2026 --

Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation Business Wire 8:30 AM

-- September 9, 2026 --

Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology Business Wire 4:01 PM

-- September 4, 2026 --

Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference Business Wire 8:30 AM

-- August 24, 2026 --

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs Business Wire 8:30 AM

-- August 10, 2026 --

AI Found an Influenza Target That Survives Viral Mutation Globe Newswire 9:10 AM

-- August 6, 2026 --

CellCarta Adds Tempus to CDx Commercialization Lab Network PRNewswire 9:15 AM

-- August 4, 2026 --

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications Business Wire 8:30 AM

-- August 3, 2026 --

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus Globe Newswire 7:45 AM

-- July 30, 2026 --

Tempus Reports Second Quarter 2026 Results Business Wire 4:01 PM

-- July 22, 2026 --

Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine Business Wire 8:30 AM

-- July 21, 2026 --

Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL Business Wire 7:01 PM

-- July 20, 2026 --

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus Globe Newswire 11:54 AM

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform Business Wire 8:30 AM

-- July 16, 2026 --

Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service Business Wire 8:30 AM

-- July 9, 2026 --

Tempus to Report Second Quarter 2026 Financial Results on July 30 Business Wire 9:00 AM

-- July 1, 2026 --

As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data PRNewswire 9:01 AM

-- June 25, 2026 --

Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers Business Wire 8:30 AM

-- June 16, 2026 --

16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap PRNewswire 9:11 AM

-- June 11, 2026 --

Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm Business Wire 8:30 AM

-- June 9, 2026 --

Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal RNA Testing Can Improve Diagnostic Clarity in Exome Testing Business Wire 6:00 AM

-- June 5, 2026 --

Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference Business Wire 4:01 PM

-- June 3, 2026 --

Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members Business Wire 8:30 AM

-- June 1, 2026 --

Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH Business Wire 8:30 AM

-- May 31, 2026 --

Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development Business Wire 8:30 AM

-- May 30, 2026 --

Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community Business Wire 8:30 AM

Tempus Introduces 'Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results Business Wire 8:00 AM

-- May 29, 2026 --

Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology Business Wire 9:15 AM

Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio Business Wire 8:15 AM

-- May 28, 2026 --

Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology Business Wire 8:30 AM

-- May 27, 2026 --

Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows Business Wire 8:33 AM

-- May 26, 2026 --

Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting Business Wire 8:32 AM

-- May 21, 2026 --

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use Business Wire 8:30 AM

-- May 14, 2026 --

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience Business Wire 8:30 AM

-- May 11, 2026 --

The Future of Intoxication Detection May Be in Your Voice Globe Newswire 8:30 AM

Ambry Genetics' CARE Program Wins 2026 MedTech Breakthrough Award for "Best Overall Health Informatics Solution" Business Wire 6:00 AM